MDLN
Medline Inc.
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$36.59
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 29.9B | 28.4B | 25.5B | 23.2B | 21.4B |
| Cost of Revenue | 22.4B | 20.9B | 19.2B | 18.0B | 16.9B |
| Gross Profit | 7.5B | 7.5B | 6.3B | 5.2B | 4.6B |
| Operating Expenses | |||||
| R&D Expense | — | — | 67.0M | 60.0M | 58.0M |
| SG&A Expense | 4.9B | 4.5B | 4.0B | 3.8B | 3.6B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 772.0M | 782.0M | (42.0M) | (88.0M) | 11.0M |
| Total Operating Expenses | 5.7B | 5.3B | 4.1B | 3.8B | 3.7B |
| Cost and Expenses | 28.1B | 26.2B | 23.3B | 21.8B | 20.6B |
| Operating Income (EBIT) | 1.8B | 2.2B | 2.2B | 1.4B | 870.0M |
| Non-Operating | |||||
| Interest Income | 113.0M | — | 280.0M | 237.0M | 27.0M |
| Interest Expense | 727.0M | 812.0M | 1.3B | 1.4B | 911.0M |
| Net Interest Income | (614.0M) | (812.0M) | (1.0B) | (1.1B) | (884.0M) |
| Other Non-Op Income/Expense | (739.0M) | (964.0M) | (979.0M) | (1.2B) | (860.0M) |
| Non-Operating Income (excl Interest) | 207.0M | 964.0M | (330.0M) | (195.0M) | (51.0M) |
| EBT (Pre-Tax Income) | 1.1B | 1.2B | 1.2B | 264.0M | 10.0M |
| Income Tax Expense | 197.0M | 91.0M | 46.0M | 30.0M | 35.0M |
| Bottom Line | |||||
| Net Income | 691.0M | 1.2B | 1.2B | 234.0M | (25.0M) |
| Earnings from Cont. Ops | 880.0M | 1.2B | 1.2B | 234.0M | (25.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 690.0M | 1.2B | 1.2B | 234.0M | (25.0M) |
| Per Share | |||||
| Basic EPS | $0.86 | $1.43 | $1.52 | $0.30 | ($0.03) |
| Diluted EPS | $0.86 | $1.43 | $1.52 | $0.30 | ($0.03) |
| Revenue Per Share | $34.93 | $35.01 | $32.41 | $29.51 | $27.25 |
| Shares | |||||
| Basic Shares Outstanding | 857.0M | 812.0M | 787.1M | 787.1M | 787.1M |
| Diluted Shares Outstanding | 861.0M | 812.0M | 787.1M | 787.1M | 787.1M |
| Profitability Metrics | |||||
| EBITDA | 2.5B | 2.0B | 3.5B | 2.6B | 1.9B |
| D&A | 939.0M | 704.0M | 977.0M | 951.0M | 933.0M |
| EBIT | 1.6B | 1.2B | 2.6B | 1.6B | 921.0M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026